MAA for gout treatment lesinurad accepted by European Medicines Agency
AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets.
Trial of AstraZeneca heart drug meets primary endpoint
Study shows that both 60mg and 90mg doses of AstraZeneca's BRILINTA® (BRILIQUE™ in the UK) demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack.
MedImmune and Omnis Pharmaceuticals focus on development of oncolytic viruses
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals, a privately-held biotechnology company focused on the development of oncolytic viruses.
Lynparza™ approved in EU as first-in-class treatment for advanced BRCA-mutated ovarian cancer
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete…
AstraZeneca & Amgen present results from Phase III AMAGINE-1 study evaluating brodalumab
First Presentation of Phase III Data From Brodalumab Psoriasis Program
MOVENTIG® approved in the European Union for opioid-induced constipation
First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives.
New drug application for IRESSA accepted by US Food and Drug Administration
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test.
AstraZeneca and Lilly initiate pivotal clinical trial for patients with early Alzheimer’s
AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. They aim to enrol more than 1,500 patients in 15 countries.
AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines
AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AstraZeneca MRC UK Centre for Lead Discovery to be built in Cambridge.
Amgen and AstraZeneca announce positive results from final trial of psoriasis treatment
Study met all primary endpoints against Stelara® (ustekinumab)and placebo. Three pivotal studies form the basis for global regulatory filings, planned for 2015.
Duaklir® Genuair® approved in the European Union for COPD
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca strategy on track to deliver sustainable growth and value through innovation
AstraZeneca will today provide an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth
AstraZeneca and Isis Pharmaceuticals to co-develop targeted oligonucleotide delivery methods
AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.
AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014
Amgen and AstraZeneca announce positive results from trial of psoriasis treatment
Amgen and AstraZeneca announce positive results from second pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis.
AstraZeneca presents new data from its growing inflammation and autoimmunity pipeline
AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from the company’s growing inflammation and autoimmunity portfolio at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts, 14-19 November 2014.
AstraZeneca PLC reports third quarter of growth
Pascal Soriot, AstraZeneca's Chief Executive Officer, commenting on the company's third quarter and nine months 2014 results, said: "I’m pleased to report our third consecutive quarter of revenue growth, driven by a strong contribution from our growth platforms."
AstraZeneca to divest Myalept to Aegerion
AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalised lipodystrophy.
AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology
Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers
AstraZeneca, Pharmacyclics and Janssen partner on immuno-oncology combination trials
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development, LLC today announced that they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton’s tyrosine kinase inhibitor, co-developed by Pharmacyclics and Janssen…
AstraZeneca completes strategic transaction with Almirall in respiratory disease
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company.
US FDA approves once-daily XIGDUO™ XR tablets for adults with Type 2 Diabetes
First US approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
AstraZeneca has today launched a programme aimed at tackling the burden of hypertension in Africa.
Lynparza™ (olaparib) receives positive CHMP opinion in the EU
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian,…
AstraZeneca strengthens partnership with the University of Cambridge
AstraZeneca, together with its global biologics research and development arm, MedImmune, today announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.